Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

Blood (2021) 138 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2021-146021

Published: 2021

Journal Articles

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

H. Marijke van den Berg, Kathelijn Fischer, Manuel Carcao, Hervé Chambost, Gili Kenet, Karin Kurnik, Chris Königs, Christoph Male, Elena Santagostino, Rolf Ljung

Blood (2019) 134 (3): 317–320.

https://doi.org/10.1182/blood.2019000658

Published: 2019

Includes: Supplemental data

Journal Articles

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Blood (2018) 132 (Supplement 1): 2472.

https://doi.org/10.1182/blood-2018-99-114518

Published: 2018

Journal Articles

Gastrointestinal Bleeding and Angiodysplasia in Von Willebrand Disease: Results from the Ongoing French HRQoL Study: Wish-Qol

Annie Borel-Derlon, MD PhD, Dominique Desprez, MD, Fabienne Volot, MD, Herve Chambost, MD PhD, Sophie Bayard, MD, Catherine Chatelanaz, Catherine Doriat-Robin, Yves Gruel, MD PhD, Agnès Veyradier, Sr., MD PhD, Jenny Goudemand, MD PhD, Sylvia Von Mackensen, PhD

Blood (2017) 130 (Supplement 1): 4866.

https://doi.org/10.1182/blood.V130.Suppl_1.4866.4866

Published: 2017

Journal Articles

Benefit of Early Treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in Patients with Hemophilia a or B with Inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-Interventional SMART-7 ™ Study

Gary Benson, Hervé Chambost, Francesco Demartis, Soraya Benchikh El Fegoun, Katarina Cepo, Lene Sommer, Kaan Kavakli

Blood (2016) 128 (22): 1439.

https://doi.org/10.1182/blood.V128.22.1439.1439

Published: 2016

Journal Articles

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Blood (2016) 128 (22): 327.

https://doi.org/10.1182/blood.V128.22.327.327

Published: 2016

Journal Articles

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Blood (2016) 128 (22): 3774.

https://doi.org/10.1182/blood.V128.22.3774.3774

Published: 2016

Journal Articles

Metabolic Syndrome in Long-Term Survivors of Childhood Acute Leukemia Treated without Hematopoietic Stem Cell Transplantation: An L.E.Α. Study

Blood (2016) 128 (22): 695.

https://doi.org/10.1182/blood.V128.22.695.695

Published: 2016

Journal Articles

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product

Thierry Calvez, Hervé Chambost, Patrick Lutz, Chantal Rothschild, Jenny Goudemand

Blood (2015) 125 (24): 3817–3819.

https://doi.org/10.1182/blood-2015-02-622167

Published: 2015

Includes: Supplemental data

Journal Articles

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Thierry Calvez, Hervé Chambost, Ségolène Claeyssens-Donadel, Roseline d’Oiron, Véronique Goulet, Benoît Guillet, Virginie Héritier, Vanessa Milien, Chantal Rothschild, Valérie Roussel-Robert, Christine Vinciguerra, Jenny Goudemand

Blood (2014) 124 (23): 3398–3408.

https://doi.org/10.1182/blood-2014-07-586347

Published: 2014

Includes: Supplemental data

Journal Articles

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

Blood (2013) 121 (20): 4046–4055.

https://doi.org/10.1182/blood-2012-09-457036

Published: 2013

Includes: Supplemental data

Journal Articles

Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities

Marion Le Meignen, Pascal Auquier, Vincent Barlogis, Nicolas Sirvent, Audrey Contet, Marie-Claude Simeoni, Claire Galambrun, Marilyne Poirée, Pascal Chastagner, Barbara Play, Virginie Villes, Julie Berbis, Hervé Chambost, Pierre Bordigoni, Gérard Michel

Blood (2011) 118 (6): 1481–1489.

https://doi.org/10.1182/blood-2011-01-332866

Published: 2011

Journal Articles

Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia

Claire Oudin, Marie-Claude Simeoni, Nicolas Sirvent, Audrey Contet, Audrey Begu-Le Coroller, Pierre Bordigoni, Catherine Curtillet, Maryline Poirée, Isabelle Thuret, Barbara Play, Mara Carazza Massot, Pascal Chastagner, Hervé Chambost, Pascal Auquier, Gérard Michel

Blood (2011) 117 (17): 4442–4448.

https://doi.org/10.1182/blood-2010-09-304899

Published: 2011

Journal Articles

Identification of Escape Mechanisms Involved in the Absence of Viral Control Despite Activation of Both Innate (natural killer and gammadelta T cells) and Virus-Specific T Cells in Children with CMV or EBV Disease Following Cord Blood Transplantation.

Laure Farnault, Gerard Michel, MD, Herve Chambost, Didier Blaise, MD, Sabine Furst, MD, Felix Montero, Ph.D., Emmanuel Gautherot, Ph.D., Julie gertner-Dardenne, Ivan Hirsch, Francoise gondois-Rey, Daniel Olive, MD, PhD

Blood (2009) 114 (22): 2659.

https://doi.org/10.1182/blood.V114.22.2659.2659

Published: 2009

Journal Articles

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Roseline d’Oiron, Jean Maurice Lavergne, Jenny Goudemand, Annie Borel-Derlon, Claude Guerois, Chantal Rothschild, Kathelijne Peerlinck, Herve Chambost, Natalie Stieltjes, the Belgian French MHAI Study Group

Blood (2004) 104 (11): 3088.

https://doi.org/10.1182/blood.V104.11.3088.3088

Published: 2004

NARROW

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Gastrointestinal Bleeding and Angiodysplasia in Von Willebrand Disease: Results from the Ongoing French HRQoL Study: Wish-Qol

Benefit of Early Treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in Patients with Hemophilia a or B with Inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-Interventional SMART-7 ™ Study

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Metabolic Syndrome in Long-Term Survivors of Childhood Acute Leukemia Treated without Hematopoietic Stem Cell Transplantation: An L.E.Α. Study

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities

Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia

Identification of Escape Mechanisms Involved in the Absence of Viral Control Despite Activation of Both Innate (natural killer and gammadelta T cells) and Virus-Specific T Cells in Children with CMV or EBV Disease Following Cord Blood Transplantation.

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only